Sharekhan

Cohance Lifesciences Ltd

Wed 21/05/2025,15:55:55 NSE: COHANCE

₹ 1075.20 19.70 (1.87%)
BUY NOW Buy Cohance Lifesciences Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Cohance Lifesciences Ltd

Wed 21/05/2025,16:1:0

Cohance Lifesciences Ltd

Wed 21/05/2025,15:55:55 | NSE : COHANCE

₹ 1075.2019.70 (1.87%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 1055.50

Previous Close

₹ 1055.50

Volume

221782

Mkt Cap ( Rs. Cr)

₹27370.82

High

₹ 1082.80

Low

₹ 1043.70

52 Week High

₹ 1360.00

52 Week Low

₹ 598.00

Book Value Per Share

₹ 77.71

Dividend Yield

0.00

Face Value

₹ 1.00

What’s Your Call?

Collective community sentiment on Cohance Lifesciences Ltd

Your Vote -

Buy

61.54%

Hold

23.08%

Sell

15.38%

61.54%

13 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

1075.20

28

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

28

Option Chain

Analyzes market sentiment, predicts Cohance Lifesciences Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Cohance Lifesciences - Analysts/Institutional Investor Meet/Con. Call Updates

    19 May 2025, 12:50PM Cohance Lifesciences Limited has informed the Exchange about Schedule of meet

  • Suven Pharmaceutical - Change In The Name And Trading Symbol

    13 May 2025, 7:59PM Change in the name and trading symbol

  • Suven Pharmaceutical - General Updates

    13 May 2025, 7:57PM Suven Pharmaceuticals Limited has informed the Exchange about General Updates

  • Suven Pharmaceutical - Name and Symbol Change

    13 May 2025, 5:54PM SUVENPHAR: Members of the Exchange are hereby informed that the name of Suven Pharmaceuticals Limited shall be changed to Cohance Lifesciences Limited

  • Suven Pharmaceutical - Disclosure under SEBI Takeover Regulations

    12 May 2025, 11:02AM Jusmiral Holdings Limited has submitted to the Exchange a copy of Disclosures under Regulation 10(6)-Report to stock Exchange in respect of any acquis

  • Suven Pharmaceutical - Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regu

    12 May 2025, 10:12AM The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SE

  • Suven Pharmaceutical - Announcement under Regulation 30 (LODR)-Allotment

    9 May 2025, 9:00AM Allotment of shares pursuant to scheme of amalgamation

  • Suven Pharmaceutical - General Updates

    9 May 2025, 8:59AM Suven Pharmaceuticals Limited has informed the Exchange about allotment of shares pursuant to the scheme of amalgamation

  • Suven Pharma rebrands as Cohance Lifesciences to reflect global CDMO vision

    8 May 2025, 9:15AM Suven Pharmaceuticals Limited has officially rebranded as Cohance Lifesciences Limited, signaling a strategic transformation into a specialized, techn

  • Suven Pharmaceutical - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    7 May 2025, 8:10PM Press release regarding change in name of the Company

  • Suven Pharmaceutical - Press Release

    7 May 2025, 8:09PM Suven Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 07, 2025, titled ""Press release regarding change in name

  • Suven Pharmaceutical - Name Change

    7 May 2025, 11:34AM Suven Pharmaceuticals Limited has informed the Exchange that the name has been changed to Cohance Lifesciences Limited

  • Suven Pharmaceutical - General Updates

    7 May 2025, 11:28AM Suven Pharmaceuticals Limited has informed the Exchange about change of name of the Company to Cohance Lifesciences Limited

  • Suven Pharmaceutical - Announcement under Regulation 30 (LODR)-Change of Company Name

    7 May 2025, 11:30AM Change of name of the Company to Cohance Lifesciences Limited

  • Suven Pharmaceutical - Record Date

    25 Apr 2025, 8:42PM Suven Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Merger/HiveOff is 08-May-2025.

  • Suven Pharmaceutical - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    25 Apr 2025, 1:03PM Press Release

  • Suven Pharmaceutical - Press Release

    25 Apr 2025, 1:02PM Suven Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 25, 2025, titled ""Press Release"".

  • Suven Pharmaceutical - Intimation Of Effective Date Of Merger And Record Date

    25 Apr 2025, 11:41AM Intimation of Effective Date of merger and Record Date

  • Suven Pharmaceutical - General Updates

    25 Apr 2025, 11:40AM Suven Pharmaceuticals Limited has informed the Exchange about Intimation of Effective Date of merger and Record Date

  • Suven Pharmaceutical - Update On Merger

    22 Apr 2025, 11:23PM Update on merger

  • Suven Pharmaceutical - General Updates

    22 Apr 2025, 11:23PM Suven Pharmaceuticals Limited has informed the Exchange about update on Merger

  • Suven Pharmaceutical has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    17 Apr 2025, 9:00PM As of March 2025, 50.10% is owned by Foreign Promoters and 49.90% by Public. <p align=justify> Institutional holds 27.65% (Insurance Companies 3.26%)

  • Suven Pharmaceutical - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    7 Apr 2025, 8:30PM Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations

  • Suven Pharmaceutical - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    7 Apr 2025, 8:29PM Suven Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

  • Suven Pharmaceutical - General Updates

    2 Apr 2025, 11:19PM Suven Pharmaceuticals Limited has informed the Exchange about General Updates

  • Suven Pharmaceutical - General Updates

    1 Apr 2025, 11:39PM Suven Pharmaceuticals Limited has informed the Exchange about General Updates

  • Suven Pharmaceutical - Cautionary Email Received From The Stock Exchange

    1 Apr 2025, 11:38PM Cautionary email received from the stock exchange

  • Suven Pharmaceutical - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    28 Mar 2025, 8:15PM SUVEN PHARMACEUTICALS LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transf

  • Suven Pharmaceutical - Resignation

    28 Mar 2025, 8:10PM Suven Pharmaceuticals Limited has informed the Exchange regarding Resignation of Mr Subba Raju Komaravolu as Senior Management Personnel of the compan

  • Suven Pharmaceutical - Announcement under Regulation 30 (LODR)-Change in Management

    28 Mar 2025, 8:10PM Resignation of Senior Management Personnel

  • Suven Pharmaceutical - Updates

    27 Mar 2025, 9:47PM Suven Pharmaceuticals Limited has informed the Exchange regarding 'Update on merger'.

  • Suven Pharmaceutical - Update On Merger

    27 Mar 2025, 9:46PM Update on Merger

  • Suven Pharmaceutical - Trading Window-XBRL

    27 Mar 2025, 6:10PM SUVEN PHARMACEUTICALS LIMITED has informed the Exchange about Closure of Trading Window

  • Suven Pharmaceutical - Board Meeting Intimation

    27 Mar 2025, 6:06PM SUVEN PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 28-May-2025 to inter-alia consider and approve the Audited F

  • Suven Pharmaceutical - Trading Window

    26 Mar 2025, 5:14PM Suven Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulat

  • Suven Pharmaceutical - Board Meeting Intimation for To Consider And Approve The Financial Results For The Period Ended March

    26 Mar 2025, 5:11PM Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2025 ,inter alia, to conside

  • Suven Pharmaceutical - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    25 Mar 2025, 7:59PM Investors Meet

  • Suven Pharmaceutical - Analysts/Institutional Investor Meet/Con. Call Updates

    25 Mar 2025, 7:58PM Suven Pharmaceuticals Limited has informed the Exchange about Schedule of meet

  • Suven Pharmaceutical - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    6 Mar 2025, 7:39PM Investors Meet

  • Suven Pharmaceutical - Analysts/Institutional Investor Meet/Con. Call Updates

    6 Mar 2025, 7:37PM Suven Pharmaceuticals Limited has informed the Exchange about Schedule of meet

  • Suven Pharmaceutical - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    6 Mar 2025, 7:33PM Investors Meet

  • Suven Pharmaceutical - Analysts/Institutional Investor Meet/Con. Call Updates

    6 Mar 2025, 7:32PM Suven Pharmaceuticals Limited has informed the Exchange about Schedule of meet

  • Suven Pharmaceutical - Announcement under Regulation 30 (LODR)-Credit Rating

    28 Feb 2025, 3:32PM Credit Rating

  • Suven Pharmaceutical - Credit Rating

    28 Feb 2025, 3:31PM Suven Pharmaceuticals Limited has informed the Exchange about Credit Rating

  • Suven Pharmaceutical - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    24 Feb 2025, 8:04PM Investor Meet intimation

  • Suven Pharmaceutical - Analysts/Institutional Investor Meet/Con. Call Updates

    24 Feb 2025, 8:02PM Suven Pharmaceuticals Limited has informed the Exchange about Schedule of meet

  • Suven Pharmaceuticals

    23 Dec 2024 , 12:39PM The drugmaker acquired 56% stake in US-based NJ Bio Inc. for $64.4 million. (Rs. 533 crore)

  • Suven Pharmaceutical up on to buy stake in Hyderabad based CDMO

    14 Jun 2024 , 11:35AM Shares of Suven Pharmaceuticals rose by 5.65% to Rs. 705, as the company is going to acquire stake in Sapala Organics

  • Suven Pharmaceuticals

    26 Feb 2024 , 10:27AM Active Pharmaceutical Ingredients and Formulations facilities (Unit-3 and Unit-5, respectively) in Pashamylaram completed the Pre-Approval Inspections (PAI) and Good Manufacturing Practices (GMP) inspections by the US Food & Drug Administration. The inspection was conducted from February 12, 2024, to February 23, 2024, and no Form 483 has been issued as a result of the inspection. (Positive).

  • Suven Pharma gets nod from Chemical & Fertilizer Ministry for acquisition.

    26 Sep 2023 , 12:27PM Suven Pharma receives approval from Chemical & Fertilizer Ministry for acquisition of up to 76.1% stake in co by Berhyanda

  • Suven Pharma

    26 Dec 2022 , 11:24AM Suven Pharma is being bought out entirely by Advent International. Advent’s offer has been accepted by Suven’s board. Blackstone was another contender for the same. Promoters Venkateswarlu Jasti and his family own 60% of the company. Advent will buy 51% of the promoter’s stake in the company and launch an open offer for an additional 26%. Advent is expected to pay close to Friday’s market price of Rs 500/share - Rs 504/share to buy the promoter’s stake, implying a payout of Rs 6,350 crore. Depending on the open offer, the final deal size could cross Rs. 8,100 Cr. This entails an EV/EBITDA multiple of 14x Suven’s LTM EBITDA, which is in line with the deals in the pharma space. Positive.

  • Advent to acquire significant stake in Suven Pharma

    26 Dec 2022 , 9:46AM Advent International to acquire a significant stake in Suven Pharmaceuticals from the Jasti family

  • Suven Pharma USFDA completes inspection of Casper Unit

    4 Oct 2022 , 1:25PM Casper Pharma Receives EIR from USFDA for its PAI

  • Suven Pharmaceuticals

    1 Aug 2022 , 10:00AM Suven Pharmaceuticals: The USFDA has completed the pre-approval inspection at wholly owned subsidiary - Casper Pharma’s formulations manufacturing facility at Hyderabad. The facility was inspected between 25th July to 29th July 2022 and the inspection ended with no observations being issued, which is positive, though we don’t have any coverage on the stock

  • Suven Pharma to acquire Hyderabad-based formulation co Casper Pharma for Rs 155. cr

    5 Apr 2022 , 2:19PM Suven Pharma board approves the investments by way of purchase of entire (100%) share capital from the existing shareholders of Casper Pharma

  • Suven Pharmaceuticals trades strong

    24 Mar 2022 , 12:29PM Shares of Suven Pharmaceuticals rises nearly 5% to Rs. 617

  • Suven Pharmaceuticals enters into agreement with CSIR

    11 Jun 2021 , 2:49PM CSIR-IICT and SUVEN Pharmaceutical, joined hands for the process technology transfer and manufacture of anti COVID drugs Molnupiravir and 2-DG

  • Suven Pharma

    11 Jun 2021 , 9:16AM Suven Pharma: The company has entered in to an MOU arrangement with CSIR-Indian Institute of Chemical Technology (IICT) Hyderabad and CSIR-National Institute of Interdisciplinary Science & Technology for the process technology transfer and manufacturing of the anti-Covid drug, Molnupiravir. The antiviral drug was initially developed to treat influenza and is repurposed to completely suppress the Covid virus transmission with in 24 hours. This is positive for Suven as the demand for the drug could be higher given the higher Covid cases in the country

  • Suven Pharmaceuticals

    27 Apr 2020 , 12:39PM As per media reports a massive fire has been reported at pharma research and manufacturing company in Telangana (Hyderabad). The fire was in the building of Suven Pharmaceuticals Ltd in Jeediemtla Area.
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Cohance Lifesciences Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 2094.4715 1818.5426 1616.2667 1206.4118 968.1203
Liabilities 2094.4715 1818.5426 1616.2667 1206.4118 968.1203
Equity 25.4565 25.4565 25.4565 25.4565 12.7282
Gross Profit 409.8999 583.0776 579.9883 440.5217 385.1457
Net Profit 304.8161 432.6025 558.0988 308.6469 270.0802
Cash From Operating Activities 370.6473 484.1702 269.8946 329.7266 367.7789
NPM(%) 29.73 32.52 42.27 30.56 32.39
Revenue 1024.9932 1330.0798 1320.2221 1009.7185 833.7898
Expenses 615.0933 747.0022 740.2338 569.1968 448.6441
ROE(%) 15.4 21.86 28.21 15.6 13.65

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
09 Sep 2022 5 500 0 491.1
09 Sep 2022 1 100 0 468.7
13 May 2022 1 100 0 586
15 Feb 2022 2 200 0 551.45
15 Feb 2022 1 100 0 538.35
13 Aug 2021 1 100 0 496.45
17 Feb 2021 1 100 0 480.15

Peers

Other companies within the same industry or sector that are comparable to Cohance Lifesciences Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 810.15 -0.84 26.88 602.05 301.39 0.62
Lotus Eye Hospital and Institute Ltd 74.06 0.78 308.58 2193.80 14.01 0.68
Vaishali Pharma Ltd 12.85 -1.15 428.33 1130.77 2.76 0.00
Astec Lifesciences Ltd 701.25 -1.59 0.00 2068.57 -687.11 0.00

Company Info

The Company was incorporated as a public limited company under the Companies Act, 2013, in Hyderabad, Telangana,India, pursuant to a certificate of incorporation dated November 6, 2018 issued by the Registrar of Companies,Telangana, at Hyderabad. 2020 -Suven Pharmaceuticals Ltd. has issued Bonus Shares in the Ratio of 1:1. 2021 -CSIR-IICT and SUVEN Pharmaceuticals Ltd., joined hands for the process technology transfer and manufacture of anti COVID drugs Molnupiravir and 2-DG. 2022 -Advent to acquire significant stake in Suven Pharmaceuticals from Jasti family. -Suven Pharmaceuticals approves acquisition of Casper Pharma.

The Company was incorporated as a public limited company under the Companies Act, 2013, in Hyderabad, Telangana,India, pursuant to a certificate of incorporation dated November 6, 2018 issued by the Registrar of Companies,Telangana, at Hyderabad. 2020 -Suven Pharmaceuticals Ltd. has issued Bonus Shares in the Ratio of 1:1. 2021 -CSIR-IICT and SUVEN Pharmaceuticals Ltd., joined hands for the process technology transfer and manufacture of anti COVID drugs Molnupiravir and 2-DG. 2022 -Advent to acquire significant stake in Suven Pharmaceuticals from Jasti family. -Suven Pharmaceuticals approves acquisition of Casper Pharma.

Read More

Parent Organisation

Cohance Lifesciences Ltd.

Founded

06/11/2018

Managing Director

Dr.V Prasada Raju

NSE Symbol

COHANCEEQ

FAQ

The current price of Cohance Lifesciences Ltd is ₹ 1075.20.

The 52-week high for Cohance Lifesciences Ltd is ₹ 1082.80 and the 52-week low is ₹ 1043.70.

The market capitalization of Cohance Lifesciences Ltd is currently ₹ 27370.82. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Cohance Lifesciences Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Cohance Lifesciences Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Cohance Lifesciences Ltd shares.

The CEO of Cohance Lifesciences Ltd is Dr.V Prasada Raju, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT